# Cronos Group Inc.: overview

CRON · Nasdaq · CIK 1656472 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cron.md) · [Financials](/companies/cron/financials.md) · [Filings](/companies/cron/filings.md) · [Insiders](/companies/cron/insiders.md)

Latest reported revenue: [$53.0m](/filings/0001656472-26-000051.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001656472-26-000051).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [34.3](/filings/0001656472-25-000101.md) | [30.3 d](/filings/0001656472-26-000016.md) | [32.3](/filings/0001656472-26-000033.md) | [33.5](/filings/0001656472-26-000051.md) | [36.3](/filings/0001656472-25-000101.md) | [44.5 d](/filings/0001656472-26-000016.md) | [45.2](/filings/0001656472-26-000033.md) | [53.0](/filings/0001656472-26-000051.md) |
| Gross margin | % | [10.5%](/filings/0001656472-25-000101.md) | [35.7% d](/filings/0001656472-26-000016.md) | [42.6%](/filings/0001656472-26-000033.md) | [43.4%](/filings/0001656472-26-000051.md) | [50.4%](/filings/0001656472-25-000101.md) | [36.4% d](/filings/0001656472-26-000016.md) | [42.4%](/filings/0001656472-26-000033.md) | [53.7%](/filings/0001656472-26-000051.md) |
| Operating margin | % | [(98.2%)](/filings/0001656472-25-000101.md) | [(37.5%) d](/filings/0001656472-26-000016.md) | [(12.6%)](/filings/0001656472-26-000033.md) | [(15.9%)](/filings/0001656472-26-000051.md) | [(1.4%)](/filings/0001656472-25-000101.md) | [(16.8%) d](/filings/0001656472-26-000016.md) | [(4.1%)](/filings/0001656472-26-000033.md) | [14.0%](/filings/0001656472-26-000051.md) |
| Net margin | % | [24.4%](/filings/0001656472-25-000101.md) | [144.3% d](/filings/0001656472-26-000016.md) | [19.0%](/filings/0001656472-26-000033.md) | [(118.7%)](/filings/0001656472-26-000051.md) | [71.4%](/filings/0001656472-25-000101.md) | [(4.1%) d](/filings/0001656472-26-000016.md) | [30.4%](/filings/0001656472-26-000033.md) | [60.5%](/filings/0001656472-26-000051.md) |
| Diluted EPS | $ per share | [0.02](/filings/0001656472-25-000101.md) | not reported | [0.02](/filings/0001656472-26-000033.md) | [(0.10)](/filings/0001656472-26-000051.md) | [0.07](/filings/0001656472-25-000101.md) | not reported | [0.04](/filings/0001656472-26-000033.md) | [0.09](/filings/0001656472-26-000051.md) |
| Free cash flow | $m | [5.2 d](/filings/0001656472-25-000101.md) | [4.2 d](/filings/0001656472-26-000016.md) | [(17.4)](/filings/0001656472-26-000033.md) | [(1.0) d](/filings/0001656472-26-000051.md) | [8.8 d](/filings/0001656472-25-000101.md) | [9.7 d](/filings/0001656472-26-000016.md) | [9.0](/filings/0001656472-26-000033.md) | [22.3 d](/filings/0001656472-26-000051.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [64.6](/filings/0001656472-24-000021.md) | [86.7](/filings/0001656472-25-000014.md) | [87.2](/filings/0001656472-26-000016.md) | [118](/filings/0001656472-26-000016.md) | [147](/filings/0001656472-26-000016.md) |
| Gross margin | % | [(27.3%)](/filings/0001656472-24-000021.md) | [17.8%](/filings/0001656472-25-000014.md) | [13.7%](/filings/0001656472-26-000016.md) | [21.4%](/filings/0001656472-26-000016.md) | [42.8%](/filings/0001656472-26-000016.md) |
| Operating margin | % | [(452.2%)](/filings/0001656472-24-000021.md) | [(128.4%)](/filings/0001656472-25-000014.md) | [(97.2%)](/filings/0001656472-26-000016.md) | [(65.1%)](/filings/0001656472-26-000016.md) | [(11.9%)](/filings/0001656472-26-000016.md) |
| Net margin | % | [(613.5%)](/filings/0001656472-24-000021.md) | [(194.5%)](/filings/0001656472-25-000014.md) | [(84.8%)](/filings/0001656472-26-000016.md) | [34.9%](/filings/0001656472-26-000016.md) | [(6.4%)](/filings/0001656472-26-000016.md) |
| Diluted EPS | $ per share | [(1.07)](/filings/0001656472-24-000021.md) | [(0.45)](/filings/0001656472-25-000014.md) | [(0.19)](/filings/0001656472-26-000016.md) | [0.11](/filings/0001656472-26-000016.md) | [(0.02)](/filings/0001656472-26-000016.md) |
| Free cash flow | $m | [(165)](/filings/0001656472-24-000021.md) | [(92.4)](/filings/0001656472-25-000014.md) | [(45.3)](/filings/0001656472-26-000016.md) | [6.4](/filings/0001656472-26-000016.md) | [0.1](/filings/0001656472-26-000016.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cron/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $24.6m | 8,840,503 |  | Added +1,222,276 |
| [Chescapmanager LLC](/funds/1697162.md) | 2026-06-30 | $22.1m | 7,942,737 |  | Unchanged |
| [Tidal Investments LLC](/funds/1600064.md) | 2026-06-30 | $10.5m | 3,767,849 |  | Reduced −259,043 |
| [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $8.5m | 3,048,254 |  | Added +369,203 |
| [MACKENZIE FINANCIAL CORP](/funds/919859.md) | 2026-06-30 | $6.3m | 1,597,039 |  | New +1,597,039 |
| [ARROWSTREET CAPITAL, LIMITED PARTNERSHIP](/funds/1164508.md) | 2026-06-30 | $5.5m | 1,992,855 |  | New +1,992,855 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $4.8m | 1,742,149 |  | Reduced −267,400 |
| [CIBC WORLD MARKET INC.](/funds/1421224.md) | 2026-06-30 | $3.8m | 1,383,299 |  | Added +36,479 |
| [MMCAP International Inc. SPC](/funds/1304857.md) | 2026-06-30 | $2.8m | 999,490 |  | Unchanged |
| [Quinn Opportunity Partners LLC](/funds/1633275.md) | 2026-06-30 | $2.7m | 969,033 |  | Unchanged |

## Recent filings

[All 494 filings](/companies/cron/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-15 | 11:02 ET | [8-K](/filings/0001656472-26-000061.md) | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001656472-26-000061 |
| 2026-09-11 | 20:14 ET | [8-K](/filings/0001656472-26-000058.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001656472-26-000058 |
| 2026-08-07 | 21:03 ET | [8-K/A](/filings/0001656472-26-000053.md) | 5.07 Shareholder vote results | 0001656472-26-000053 |
| 2026-08-06 | 11:32 ET | [10-Q](/filings/0001656472-26-000051.md) | Quarterly report, period 2026-06-30 | 0001656472-26-000051 |
| 2026-08-06 | 11:31 ET | [8-K](/filings/0001656472-26-000050.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001656472-26-000050 |
| 2026-06-22 | 21:04 ET | [8-K](/filings/0001656472-26-000039.md) | 5.07 Shareholder vote results | 0001656472-26-000039 |
| 2026-05-11 | 11:33 ET | [10-Q](/filings/0001656472-26-000033.md) | Quarterly report, period 2026-03-31 | 0001656472-26-000033 |
| 2026-05-11 | 11:32 ET | [8-K](/filings/0001656472-26-000032.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001656472-26-000032 |
| 2026-04-24 | 20:40 ET | [DEF 14A](/filings/0001656472-26-000021.md) | Proxy statement, period 2025-12-31 | 0001656472-26-000021 |
| 2026-02-26 | 12:38 ET | [10-K](/filings/0001656472-26-000016.md) | Annual report, period 2025-12-31 | 0001656472-26-000016 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001656472-26-000016.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/df76ec76-9d97-4a48-b108-9d4ae914d36a)

## About the filer

- CIK: 1656472
- Tickers: CRON
- Exchange: Nasdaq
- SIC code: 2833 Medicinal Chemicals & Botanical Products
- State of incorporation: A1
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.